Male health and obesity – diagnostic and therapeutic approach
Abstract
Obesity may present as a significant medical problem for any person, regardless of age or gender. In men obesity causes considerable psychological stress, sexual dysfunction, subfertility, hypogonadism and cardiovascular conditions. These problems may form numerous pathological associations between each other, creating a vicious circle. The main factors which influence male fertility and sexual function in obesity and metabolic syndrome are imbalance of sex hormones and systemic inflammation. In many patients symptomatic treatment is necessary for above-mentioned manifestations, but it is always rational to act on their pathophysiology and to recommend to lower the body mass by diet and lifestyle modification. When it proves impossible for the patient to follow such recommendations and when behavioral approach fails, central-acting and peripheral-acting medications may be used, including orlistat, sibutramine and liraglutide. Bariatric surgery should be offered to patients with high body mass index in whom conservative management fails. Without elimination of excess body mass it is difficult to solve problems regarding sexual dysfunction, hypogonadism and subfertility in obese males. All these issues and available modes of pharmacological treatment are described in this review.
About the Authors
Safar I. Gamidov
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology; I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
MD, PhD
Taras V. Shatylko
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology
Russian Federation
Russian Federation
MD, PhD
Natig G. Gasanov
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology
Russian Federation
Russian Federation
MD
References
1. Гамидов СИ, Шатылко ТВ, Гасанов НГ, Наумов НП. Применение тадалафила по требованию при эректильной дисфункции у особых категорий пациентов. // Андрология и генитальная хирургия. — 2018. — Т. 19. — №4. — С. 15-20. [Gamidov SI, Shatylko TV, Gasanov NG, Naumov NP. The use of tadalafil on demand in specific categories of patients. Andrology and Genital Surgery. 2018;19(4):15-20. (In Russ.)] DOI:10.17650/2070-9781-2018-19-4-15-20
2. Ghosh A, Gao L, Thakur A, et al. Role of free fatty acids in endothelial dysfunction. J Biomed Sci. 2017;24(1):50. DOI:10.1186/s12929-017-0357-5
3. de Souza ILL, Barros BC, de Oliveira GA, et al. Hypercaloric Diet Establishes Erectile Dysfunction in Rat: Mechanisms Underlying the Endothelial Damage. Front Physiol. 2017;8:760. DOI:10.3389/fphys.2017.00760
4. Kim JE, Kim YW, Lee IK, et al. AMP-activated protein kinase activation by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) inhibits palmitate-induced endothelial cell apoptosis through reactive oxygen species suppression. J Pharmacol Sci. 2008;106(3):394-403. DOI:10.1254/jphs.fp0071857
5. Ryu SY, Choi YJ, Park SY, et al. Udenafil, a Phosphodiesterase 5 Inhibitor, Reduces Body Weight in High-Fat-Fed Mice. World J Mens Health. 2018;36(1):41-49. DOI:10.5534/wjmh.17028
6. Li S, Xu J, Yao W, et al. Sevoflurane pretreatment attenuates TNF-alpha-induced human endothelial cell dysfunction through activating eNOS/NO pathway. Biochem Biophys Res Commun. 2015;460(3):879-886. DOI:10.1016/j.bbrc.2015.03.126
7. Hafez G, Gonulalan U, Kosan M, et al. Acetylsalicylic acid protects erectile function in diabetic rats. Andrologia. 2014;46(9):997-1003. DOI:10.1111/and.12187
8. Bayraktar Z, Albayrak S. Antiplatelet (aspirin) therapy as a new option in the treatment of vasculogenic erectile dysfunction: a prospective randomized double-blind placebo-controlled study. Int Urol Nephrol. 2018;50(3):411-418. DOI:10.1007/s11255-018-1786-0
9. Kapoor MS, Khan SA, Gupta SK, et al. Animal models of erectile dysfunction. J Pharmacol Toxicol Methods. 2015;76:43-54. DOI:10.1016/j.vascn.2015.07.013
10. Aleid M, Muneer A, Renshaw S, et al. Early Effect of Bariatric Surgery on Urogenital Function in Morbidly Obese Men. J Sex Med. 2017;14(2):205-214. DOI:10.1016/j.jsxm.2016.12.004
11. Kun L, Pin Z, Jianzhong D, et al. Significant improvement of erectile function after Roux-en-Y gastric bypass surgery in obese Chinese men with erectile dysfunction. Obes Surg. 2015;25(5):838-844. DOI:10.1007/s11695-014-1465-x
12. Kaya E, Sikka SC, Gur S. A comprehensive review of metabolic syndrome affecting erectile dysfunction. J Sex Med. 2015;12(4):856-875. DOI:10.1111/jsm.12828
13. Patel JP, Lee EH, Mena CI, Walker CN. Effects of metformin on endothelial health and erectile dysfunction. Transl Androl Urol. 2017;6(3):556-565. DOI:10.21037/tau.2017.03.52
14. Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168(6):829-843. DOI:10.1530/EJE-12-0955
15. Hofstra J, Loves S, Van Wageningen B, et al. High prevalence of hypogonadotropic hypogonadism in men referred for obesity treatment. Neth J Med. 2008;66(3):103-109.
16. Saboor Aftab SA, Kumar S, Barber TM. The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism. Clin Endocrinol (Oxf). 2013;78(3):330-337. DOI:10.1111/cen.12092
17. Wagner IV, Kloting N, Atanassova N, et al. Prepubertal onset of obesity negatively impacts on testicular steroidogenesis in rats. Mol Cell Endocrinol. 2016;437:154-162. DOI:10.1016/j.mce.2016.08.027
18. Guo D, Wu W, Tang Q, et al. The impact of BMI on sperm parameters and the metabolite changes of seminal plasma concomitantly. Oncotarget. 2017;8(30):48619-48634. DOI:10.18632/oncotarget.14950
19. Shukla KK, Chambial S, Dwivedi S, et al. Recent scenario of obesity and male fertility. Andrology. 2014;2(6):809-818. DOI:10.1111/andr.270
20. Fan Y, Liu Y, Xue K, et al. Diet-induced obesity in male C57BL/6 mice decreases fertility as a consequence of disrupted blood-testis barrier. PLoS One. 2015;10(4):e0120775. DOI:10.1371/journal.pone.0120775
21. Palmer NO, Bakos HW, Owens JA, et al. Diet and exercise in an obese mouse fed a high-fat diet improve metabolic health and reverse perturbed sperm function. Am J Physiol Endocrinol Metab. 2012;302(7):E768-780. DOI:10.1152/ajpendo.00401.2011
22. Samavat J, Natali I, Degl’Innocenti S, et al. Acrosome reaction is impaired in spermatozoa of obese men: a preliminary study. Fertil Steril. 2014;102(5):1274-1281 e1272. DOI:10.1016/j.fertnstert.2014.07.1248
23. Liu Y, Guo Y, Song N, et al. Proteomic pattern changes associated with obesity-induced asthenozoospermia. Andrology. 2015;3(2):247-259. DOI:10.1111/andr.289
24. Duale N, Steffensen IL, Andersen J, et al. Impaired sperm chromatin integrity in obese mice. Andrology. 2014;2(2):234-243. DOI:10.1111/j.2047-2927.2013.00178.x
25. Fariello RM, Pariz JR, Spaine DM, et al. Association between obesity and alteration of sperm DNA integrity and mitochondrial activity. BJU Int. 2012;110(6):863-867. DOI:10.1111/j.1464-410X.2011.10813.x
26. Aitken RJ, Gibb Z, Baker MA, et al. Causes and consequences of oxidative stress in spermatozoa. Reprod Fertil Dev. 2016;28(1-2):1-10. DOI:10.1071/RD15325
27. Davidson LM, Millar K, Jones C, et al. Deleterious effects of obesity upon the hormonal and molecular mechanisms controlling spermatogenesis and male fertility. Hum Fertil (Camb). 2015;18(3):184-193. DOI:10.3109/14647273.2015.1070438
28. Andersen JM, Ronning PO, Herning H, et al. Fatty acid composition of spermatozoa is associated with BMI and with semen quality. Andrology. 2016;4(5):857-865. DOI:10.1111/andr.12227
29. Gangwar DK, Atreja SK. Signalling Events and Associated Pathways Related to the Mammalian Sperm Capacitation. Reprod Domest Anim. 2015;50(5):705-711. DOI:10.1111/rda.12541
30. Martinez-Soto JC, Landeras J, Gadea J. Spermatozoa and seminal plasma fatty acids as predictors of cryopreservation success. Andrology. 2013;1(3):365-375. DOI:10.1111/j.2047-2927.2012.00040.x
31. Keber R, Rozman D, Horvat S. Sterols in spermatogenesis and sperm maturation. J Lipid Res. 2013;54(1):20-33. DOI:10.1194/jlr.R032326
32. Whitfield M, Pollet-Villard X, Levy R, et al. Posttesticular sperm maturation, infertility, and hypercholesterolemia. Asian J Androl. 2015;17(5):742-748. DOI:10.4103/1008-682X.155536
33. Schisterman EF, Mumford SL, Chen Z, et al. Lipid concentrations and semen quality: the LIFE study. Andrology. 2014;2(3):408-415. DOI:10.1111/j.2047-2927.2014.00198.x
34. Reilly SM, Saltiel AR. Adapting to obesity with adipose tissue inflammation. Nat Rev Endocrinol. 2017;13(11):633-643. DOI:10.1038/nrendo.2017.90
35. Rheinheimer J, de Souza BM, Cardoso NS, et al. Current role of the NLRP3 inflammasome on obesity and insulin resistance: A systematic review. Metabolism. 2017;74:1-9. DOI:10.1016/j.metabol.2017.06.002
36. Makki K, Froguel P, Wolowczuk I. Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines. ISRN Inflamm. 2013;2013:139239. DOI:10.1155/2013/139239
37. Kyrou I, Mattu HS, Chatha K, Randeva HS. Fat Hormones, Adipokines. 2017:167-205. DOI:10.1016/b978-0-12-803111-7.00007-5
38. Samad F, Ruf W. Inflammation, obesity, and thrombosis. Blood. 2013;122(20):3415-3422. DOI:10.1182/blood-2013-05-427708
39. Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol. 2012;34(1):43-62. DOI:10.1007/s00281-011-0290-8
40. Chen R, Yan J, Liu P, et al. Plasminogen activator inhibitor links obesity and thrombotic cerebrovascular diseases: The roles of PAI-1 and obesity on stroke. Metab Brain Dis. 2017;32(3):667-673. DOI:10.1007/s11011-017-0007-3
41. Kaji H. Adipose Tissue-Derived Plasminogen Activator Inhibitor-1 Function and Regulation. Compr Physiol. 2016;6(4):1873-1896. DOI:10.1002/cphy.c160004
42. Koller A, Balasko M, Bagi Z. Endothelial regulation of coronary microcirculation in health and cardiometabolic diseases. Intern Emerg Med. 2013;8 Suppl 1:S51-54. DOI:10.1007/s11739-013-0910-5
43. Hozumi T, Eisenberg M, Sugioka K, et al. Change in coronary flow reserve on transthoracic Doppler echocardiography after a single high-fat meal in young healthy men. Ann Intern Med. 2002;136(7):523-528. DOI:10.7326/0003-4819-136-7-200204020-00009
44. Muris DM, Houben AJ, Schram MT, Stehouwer CD. Microvascular dysfunction: an emerging pathway in the pathogenesis of obesity-related insulin resistance. Rev Endocr Metab Disord. 2013;14(1):29-38. DOI:10.1007/s11154-012-9231-7
45. Campbell DJ, Somaratne JB, Prior DL, et al. Obesity is associated with lower coronary microvascular density. PLoS One. 2013;8(11):e81798. DOI:10.1371/journal.pone.0081798
46. Tona F, Serra R, Di Ascenzo L, et al. Systemic inflammation is related to coronary microvascular dysfunction in obese patients without obstructive coronary disease. Nutr Metab Cardiovasc Dis. 2014;24(4):447-453. DOI:10.1016/j.numecd.2013.09.021
47. Sorop O, van den Heuvel M, van Ditzhuijzen NS, et al. Coronary microvascular dysfunction after long-term diabetes and hypercholesterolemia. Am J Physiol Heart Circ Physiol. 2016;311(6):H1339-H1351. DOI:10.1152/ajpheart.00458.2015
48. Rodriguez-Flores M, Garcia-Garcia E, Cano-Nigenda CV, Cantu-Brito C. Relationship of obesity and insulin resistance with the cerebrovascular reactivity: a case control study. Cardiovasc Diabetol. 2014;13:2. DOI:10.1186/1475-2840-13-2
49. Carriere F, Renou C, Ransac S, et al. Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers. Am J Physiol Gastrointest Liver Physiol. 2001;281(1):G16-28. DOI:10.1152/ajpgi.2001.281.1.G16
50. Kanoski SE, Hayes MR, Skibicka KP. GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol. 2016;310(10):R885-895. DOI:10.1152/ajpregu.00520.2015
51. van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014;38(6):784-793. DOI:10.1038/ijo.2013.162
52. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314(7):687-699. DOI:10.1001/jama.2015.9676
53. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. DOI:10.1056/NEJMoa1411892
54. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443-1451. DOI:10.1038/ijo.2013.120
55. le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. The Lancet. 2017;389(10077):1399-1409. DOI:10.1016/s0140-6736(17)30069-7
56. Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016;40(8):1310-1319. DOI:10.1038/ijo.2016.52
57. Steinberg WM, Rosenstock J, Wadden TA, et al. Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program. Diabetes Care. 2017;40(7):839-848. DOI:10.2337/dc16-2684
58. Jensterle, M., Podbregar, A., Goricar, K., Gregoric, N., & Janez, A. Effects of liraglutide on obesity-associated functional hypogonadism in men, Endocrine Connections, 8 (3), 195-202.
Supplementary files
Review
For citations:
Gamidov S.I., Shatylko T.V., Gasanov N.G. Male health and obesity – diagnostic and therapeutic approach. Obesity and metabolism. 2019;16(3):29-36. (In Russ.)
Views:
7760
Email this article 
